Adoption of the income statements and the balance sheets
The Annual General Meeting approved the income statements and the balance sheets for the fiscal year 2023.
The Annual General Meeting resolved, in accordance with the proposal of the Board of Directors that no dividend should be paid for the fiscal year 2023.
The Annual General Meeting discharged the Board members and the Chief Executive Officer from liability for the fiscal year 2023.
Board of Directors
In accordance with the proposal of the Nomination Committee, the Annual General Meeting resolved that the Board of Directors shall consist of four persons and no deputies.
The Annual General Meeting resolved, in accordance with the proposal of the Nomination Committee, on re-election of Nikolaj Sörensen, Kerstin Valinder Strinnholm and Håkan Wallin as well as election of
The Annual General Meeting resolved, in accordance with the proposal of the Nomination Committee, that an aggregate annual fee of
Fees to the Auditors, for a period until the end of the next Annual General Meeting, are to be paid as per approved invoice.
Nomination Committee
The Annual General Meeting resolved, in accordance with the proposal of the Nomination Committee, that the Company shall have a Nomination Committee consisting of three members. The Nomination Committee shall comprise one representative of each of the two largest shareholders or owner groups in the Company in terms of votes as per
Principles for remuneration
The Annual General Meeting resolved to approve the
Remuneration report
The Annual General Meeting resolved to approve the
Implementation of LTI 2024
The Annual General Meeting also resolved to approve the
Authorization to issue shares
The Annual General Meeting resolved, in accordance with the proposal of the Board of Directors, to authorize the Board of Directors to, within the scope of the articles of association, with or without deviation from the shareholders' pre-emptive rights, on one or several occasions during the period until the next Annual General Meeting, resolve to increase the Company's share capital by issuing new shares, warrants and/or convertible debentures in the Company. The total number of shares, warrants and/or convertible debentures issued in accordance with this authorization may be equivalent to a maximum of twenty (20) per cent of the shares in the Company at the first time the Board of Directors makes a resolution by virtue of the authorization.
Minutes from the meeting and complete resolutions
The minutes from the Annual General Meeting will be made available at the Company and on the Company's website, www.mobergpharma.com.
For additional information, please contact:
About this information
The information was submitted for publication at 4.30 p.m CEST on
About
https://news.cision.com/moberg-pharma/r/bulletin-from-moberg-pharma-s-agm-on-may-14-th--2024,c3979715
https://mb.cision.com/Main/1662/3979715/2796660.pdf
(c) 2024 Cision. All rights reserved., source